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ABSTRAK  
Dargantes AP, Wardhana AH,  Abella JAC, Sequito MR, Reid SA, Copeman DB, Dargantes KAT. 2020. Patogenitas isolat 
Trypanosoma evansi asal Philippina dan Indonesia pada mencit serta responnya terhadap trypanosidal. JITV 26(1): 22-30. DOI: 
http://dx.doi.org/10.14334.jitv.v26i1.2508. 
Patogenitas sepuluh isolat Trypanosoma evansi asal Filipina (Mindanao) dan satu isolat asal  Indonesia (Jawa Timur) 
dipelajari dan dibandingkan. Disamping itu, studi ini juga menguji kepekaan isolat-isolat tersebut terhadap beberapa 
trypanosidal, yaitu diminazene aceturate, melarsomine dihydrochloride, suramin and quinapyramine sulphate/chloride. Sebanyak 
25 mencit diinfeksi secara interperitoneal dengan masing-masing isolat dan 20 mencit diberi perlakuan dengan 4 obat (5 
mencit/obat), sementara itu kelompok yang lain terdiri dari 5 ekor per isolat sebagai kelompok kontrol diinfeksi tanpa 
pengobatan  dan 7 ekor per isolat sebagai kelompok yang tidak diinfeksi. Pengobatan dilakukan pada 24 jam pasca infeksi dan 
parasitemia diamati setiap hari selama 35 hari. Mencit yang diinfeksi dengan isolat Filipina secara nyata mengalami kematian 
lebih awal (hari ke 5 -11) dibandingkan dengan isolat Indonesia (hari ke 14 -16).  Periode prepaten isolat Filipina juga secara 
nyata lebih pendek (3 – 8 hari) daripada isolat Indonesia (11 – 13 hari). Trypanosoma tidak terdeteksi di dalam darah mencit 
yang diinfeksi isolat Filipina setelah diobati dengan quinapyramine sulphate/chloride, melarsomine dihydrochloride atau 
suramin. Dua dari sepuluh isolat baik yang diinfeksi dengan isolat Filipina (C4 atau A9) yang kemudian diobati dengan 
diminazene aceturate masih menunjukkan parasitemia pada hari 29 dan 31. Disimpulkan bahwa isolat T. evansi dari Mindanao, 
Filipina lebih patogen dibandingkan dengan isolat dari Jawa Timur, Indonesia. Quinapyramine sulphate/chloride, melarsomine 
dihydrochloride dan suramin efektif terhadap T. evansi yang diteliti. Informasi ini sangat penting untuk meningkatkan strategi 
pengendalian Surra di Filipina dan Indonesia. 
Kata Kunci: Jawa Timur, Mindanao, Patogenitas, Resisten, Trypanosoma evansi 
ABSTRACT 
Dargantes AP, Wardhana AH, Abella JAC, Sequito MR, Reid SA, Copeman DB, Dargantes KAT. 2020. Pathogenicity of 
Philippine and Indonesian Trypanosoma evansi isolates in mice and their responses to trypanocides. JITV 26(1): 22-30. DOI: 
http://dx.doi.org/10.14334.jitv.v26i1.2508. 
 Pathogenicity of 10 isolates of T. evansi collected from  Mindanao, Philippines, and one isolate from East Java, 
Indonesia was determined and compared. The susceptibility of these isolates against diminazene aceturate, melarsomine 
dihydrochloride, suramin and quinapyramine sulphate/chloride was also tested. Twenty-five mice were infected intraperitoneally 
with each isolate and 20 were treated with the 4 drugs (5 mice/drug) while 5 infected and 7 uninfected mice served as infected-
untreated and uninfected controls, respectively. Treatment was carried out 24 hours post-infection and parasitemia was 
monitored for 35 days. Mice infected with Philippine isolates significantly died earlier (5-11 days) than those infected with the 
Indonesian isolate (14-16 days). The prepatent period for Philippine isolates (3-8 days) was significantly shorter than the 
Indonesian strain (11-13 days).  Trypanosomes were not observed in the blood of mice infected with any of the Philippine 
isolates when treated with quinapyramine sulphate/chloride, melarsomine dihydrochloride or suramin. Two of 10 mice infected 
with either C4 or A9 Philippine isolates and treated with diminazene aceturate had parasitemia on days 29 and 31, respectively. 
It is concluded that isolates of T. evansi from Mindanao, Philippines, are more pathogenic than the isolate from East Java, 
Indonesia. This study also indicated that quinapyramine sulphate/chloride, melarsomine dihydrochloride and suramin are 
effective against these T. evansi isolates from Mindanao, Philippines and East Java, Indonesia, while two of the Mindanao 
isolates are resistant to diminazene. This information is valuable in the enhancement of the control strategy against surra in the 
Philippines and Indonesia.  
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Trypanosomosis (Surra) caused by a protozoan 
parasite, Trypanosoma evansi, remains a major problem 
in livestock and wild animals. The parasite is widely 
distributed in Central and South America, Africa and 
South-east Asia including the Philippines and Indonesia 
(Boushaki et al. 2019). In some countries, the parasite 
has been also reported to infect humans (zoonotic) 
(Desquesnes et al. 2013; Chau et al. 2016; Wardhana & 
Sawitri 2018). Dewi et al. (2020) reported that the 
economic losses of surra outbreak in East Sumba of 
Indonesia were 25.7 billion rupiahs during 3 years 
(2010 – 2012) while in Mindanao, Philippines, a village 
with moderate to high surra in its livestock loses about 
US$158,000 annually (2.3 billion rupiahs) (Dobson et 
al. 2009). 
Severe outbreaks of surra in the Philippines were 
reported in South Cotabato and Agusan del Sur, 
Mindanao between 1989-1994 (McInnes et al. 2012). 
The disease spread to other provinces in the following 
years. The strain of T. evansi causing the outbreaks was 
suspected to be highly virulent, previously not present 
in the country (Lazaro et al. 2019). In Indonesia, T. 
evansi was first identified from an outbreak of the 
disease amongst horses in Semarang in 1897 (Nuryady 
et al. 2019). Furthermore, some outbreaks occurred 
subsequently in cattle and water buffaloes in East Java, 
then surra rapidly spread to other islands in Indonesia 
(Dewi et al. 2019; Sawitri et al. 2019). The parasite can 
easily spread between provinces through infected water 
buffaloes, horses and cattle brought by transmigrating 
people or dispersed by the government as part of its 
animal dispersal project (Dargantes et al. 2009; 
Desquesnes et al. 2013; Sawitri et al. 2019).  
Mekonnen et al. (2018) stated that control of surra 
normally relies on drug treatment and vector control, 
including chemoprophylaxis. The common drugs used 
for surra treatment are suramin, diminazene aceturate, 
quinapyramine and melarsomine (Gressler et al. 2015; 
Shiferaw et al. 2015; Gillingwater 2018). However, 
only two drugs, isometamidium and diminazene 
aceturate, are officially marketed in Indonesia (Dewi et 
al. 2019; Dewi et al. 2020).   
Differences in pathogenicity and drug sensitivity 
amongst isolates of T. evansi have been documented 
elsewhere but not in Mindanao (Jatau et al. 2010; 
Kamidi et al. 2018). Gressler et al. (2015) stated that the 
pathogenicity of T. evansi may vary depending on the 
strain, host species and some non-specific factors such 
as stress, concurrent infections, or epizootiological local 
conditions. 
During the past decade, several outbreaks of surra 
have occurred in Mindanao, Philippines, that caused 
high morbidity and mortality in horses, buffaloes, cattle 
and small ruminants. This pattern seems to be different 
from that described in the neighboring Indonesian 
archipelago where outbreaks only occur sporadically 
and are often localized. This raises the suspicion that 
strains of the parasite with different levels of 
pathogenicity may be present in Mindanao.  
The present study was undertaken to provide some 
of this information. The pathogenicity of 10 isolates of 
T. evansi collected from animals in different areas in 
Mindanao, Philippines, and one isolate from East Java, 
Indonesia was determined and compared. In addition, 
efficacy of four different trypanocides was also tested. 
The information generated from this endeavor is 
valuable for the enhancement of the control strategy 
against surra in Mindanao, Philippines and Indonesia.  
MATERIAL AND METHODS 
Study site and ethical approval 
The laboratory trial was done at the Animal Disease 
Diagnostic Laboratory of the College of Veterinary 
Medicine, Central Mindanao University, Philippines, 
with approval of the research protocol by the Animal 
Ethics Subcommittee of James Cook University, 
Australia (Permit no. A779-02; 2003). 
Isolates of T. evansi  
The origin of Philippine and East Javanese isolates 
of T. evansi used in this study are presented in Table 1.  
All isolates were passaged in mice twice then 
maintained in guinea pigs until tested.  
Preparation of the inoculum 
The inoculum for each isolate was prepared from 
the blood of an infected mouse. After counting the 
parasite in the blood, when parasitemia was high, a drop 
of tail blood was diluted with phosphate-buffered saline 
glucose (PBSG; pH=8.0) and viable trypanosomes were 
counted using a Neubauer hemocytometer.  Blood was 
then diluted with PBSG to provide 15 mL of inoculum 
with 5,000 trypanosomes per mL (Sawitri & Wardhana 
2017). 
Infection of laboratory mice 
A total of 352, 6-9 week-old DDY mice each 
weighing an average of 20 g were used in the trial. The 
mice were purchased from a local colony and examined 
to ensure freedom from blood parasites prior to 
infection. They were acclimatized for two weeks before 
the trial (Sawitri & Wardhana 2017). 
For each isolate, 32 mice were randomly selected, 
25 of which were each infected intraperitoneally (ip) 
with 0.2 mL of inoculum containing 1,000 T. evansi. 
For the infected mice, 4 groups of 5 were treated with 4 
trypanocides and one group of 5 served as untreated, 
infected controls. The seven uninfected mice served as 
untreated uninfected controls for each isolate. The trial 
was carried out in three batches. 
The selected mice were housed in plastic cages 
separated according to isolates, and provided with clean 
  






































T. evansi isolates 
Table 1.  Origin and dates of collection of 11 isolates stock of T. evansi used in the present study 
Code 
Origin Collection 
Species Place Date of the Stock 
C1 Horse Cacub, Marbel, South Cotabato, Mindanao, Phl 15 January 2002 
C2 Buffalo Cacub, Marbel, South Cotabato, Mindanao, Phl 15 January 2002 
C3 Buffalo Cacub, Marbel, South Cotabato, Mindanao, Phl 16 January 2002 
C4 Buffalo Cacub, Marbel, South Cotabato, Mindanao, Phl 16 January 2002 
C5 Buffalo Cacub, Marbel, South Cotabato, Mindanao, Phl 16 January 2002 
A8 Buffalo Sta. Josefa, Agusan del Sur, Mindanao, Phl 16 January 2002 
A9 Buffalo Talacogon, Agusan del Sur, Mindanao, Phl 15 January 2002 
A10 Buffalo Talacogon, Agusan del Sur, Mindanao, Phl 15 January 2002 
A11 Buffalo Talacogon, Agusan del Sur, Mindanao, Phl 15 January 2002 
A13 Buffalo Veruela, Agusan del Sur, Mindanao, Phl 16 January 2002 









Figure 1.  Mean pre-patent periods (days + SD) of 10 Philippine isolates (C1-A13) and an Indonesian isolate (EJ1) of   T. evansi in mice. Means 
with different letters are significantly different (p<0.05). 
water and commercial pelletized feed, ad libitum.  The 
cages were arranged in an open metal cabinet in a well-
ventilated room. The litter material of sterile wood 
shavings was changed every 4 days during the trial. 
Treatment with trypanocides 
Four trypanocides were tested against T. evansi 
infection in mice using the following dose regimens: 
diminazene aceturate (Berenil
®
, Hoechst, Germany) ip 
at 7 mg kg
-1 
bw; melarsomine dihydrochloride 
(Immiticide
®





, Bayer, Germany) ip at 10 
mg   kg
-1   
bw;   and   quinapyramine   sulphate/chloride 
(Triquin
TM
, Sanjivani Paranteral Limited, India) 
subcutaneously at 5 mg kg
-1 
bw. The drugs were diluted 
separately with sterile distilled water to a working 
concentration of 1-2 mg mL
-1
 and refrigerated (not 
more than 48 hours) until used. Each mouse was 
weighed using a digital weighing scale (Mettler, USA) 
and the amount of drug was calculated based on the 
dose regimen. Treatment was administered 24 hours 
after infection.  

































































Figure 2. Mean duration of survival (days + SD) of mice after infection with 10 Philippine isolates (C1-A13) and an Indonesian (EJ1) isolate of 
T. evansi. Means with different letters are significantly different (p<0.05).  
Monitoring of parasitemia and pathology 
Untreated-infected mice and the uninfected controls 
were examined daily for presence of trypanosomes in 
the blood by wet blood film taken from the tail tip 
(Villareal et al. 2013; Garba et al. 2017). The mice were 
monitored for clinical signs after infection. Treated 
mice were similarly monitored every 2 days, for 35 
days after treatment. Heart smears were made from 
each mouse that died and examined for trypanosomes. 
Necropsy was conducted of every dead mouse and 
gross lesions were noted. 
Pre-patent period and the duration of survival of 
infected, untreated mice were used as indices of 
pathogenicity. Absence of parasitemia among treated 
mice was regarded as an indicator of drug efficacy 
against T. evansi. Any surviving mouse after being 
treated using any of the four trypanocides was 
considered cured (Begolo et al. 2018).  
Analyses of data 
The statistical significance of differences (p<0.05) 
in duration of survival and pre-patent period between 
groups was determined by one-way analysis of variance 
(ANOVA) and Tukey’s honestly significantly different 
test (Tukey’s HSD) using SPSS statistical program. 
RESULTS AND DISCUSSION 
Pathogenicity 
All mice infected with any of the isolates and not 
treated with a trypanocide developed a disease and died 
subsequently. The pre-patent period and duration of 
survival varied significantly (p<0.05) amongst isolates 
(Figures 1 and 2). Pre-patent period and duration of 
survival were correlated. Mice infected with Mindanao 
isolates died earlier (5-11 days) than those infected with 
the Indonesian isolate (14-16 days) (p<0.05).  The pre-
patent period for the Mindanao isolates varied between 
3-8 days and was significantly shorter (p<0.05) than 
that of the Indonesian strain (11-13 days).  Compared to 
all 10 isolates from Mindanao, the East Javanese isolate 
had lower pathogenicity. There was also heterogeneity 
in pathogenicity of the Mindanao isolates but only one 
(A9) stood out as being significantly different (lower 
pathogenicity; p<0.05) than the others. Before death, 
mice showed signs of general weakness and 
recumbency and appeared to be tilted on one side. 
Gross lesions observed at necropsy were splenomegaly, 
hepatomegaly, petechial hemorrhages in the intestines, 
and congested spleen, kidneys and lungs. No 
differences in gross lesions between isolates were 
observed. 
This is the first attempt to compare the 
pathogenicity and drug sensitivity of different isolates 
of T. evansi from Mindanao, Philippines and an isolate 
from East Java, Indonesia. All isolates induced a fatal 
infection in mice. However, pre-patent period and 
duration of survival were significantly longer with the 
East Javanese isolate indicating that it is less pathogenic 
in mice than those taken from Mindanao, Philippines. 
The present finding on the differences of virulence of T. 
evansi isolates in Mindanao supports the observation of  
Verdillo et al. (2012) and Mekata et al. (2013) on the 
varying levels of pathogenicity among T. evansi isolates 
in the Philippines in mice. The pathogenicity of the 10 
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Mindanao T. evansi isolates can be considered as 
moderate to high while that of the East Javanese isolate 
as low to moderate based on the classification by  
Sawitri & Wardhana (2017).  Using 25 T. evansi 
isolates (collected from livestock in various regions in 
Indonesia) to infect mice and confirmed by molecular 
tools using ESAG 6/7 gene as marker, Sawitri & 
Wardhana (2017) classified the virulence levels of the 
Indonesian isolates into three, namely: high (death of 
mice less than 7 days, post-infection, pi), moderate 
(death of mice between 7–15 days, pi) and low 
virulence (death of mice more than 15 days, pi).   
Regional differences in the pathogenicity of T. 
evansi in mice have been also documented by others. 
Sawitri & Wardhana (2017) demonstrated that isolates 
of T. evansi collected from the same region in Indonesia 
had different levels of virulence in mice. In Pantanal, 
Brazil, different T. evansi isolates collected from 
domestic and wild animals showed marked 
heterogeneity in their morphology and pathogenicity in 
rodents despite demonstrating homogeneity in their 
biochemical and molecular properties (Parreira et al. 
2016). Kamidi et al. (2018) also provided additional 
evidence regarding regional differences in the virulence 
of T. evansi. 
The various pathogenicity patterns have been also 
reported among Trypanosoma vivax, T. congolense and 
T. brucei which are distributed widely among cattle in 
Africa and Latin America. Ramirez-Barrios et al. 
(2019) showed that T. vivax showed moderate to high 
pathogenicity in experimentally-infected sheep while 
varying virulence was observed for T. congolense 
isolates in mice, nude rats, and bovine (Bengaly et al. 
2002; Giordani et al. 2016). Likewise, differences in 
virulence was also detected among T. brucei gambiense 
isolates in Balb/c mice (Holzmuller et al. 2008). 
Queiroz et al. (2000) indicated that pathogenicity as 
measured by survival time after infection could be 
regarded as a biological marker for the heterogeneity of 
isolates of T. evansi. However, whether heterogeneity 
in mice is a reflection of similar heterogeneity of 
pathogenicity in domestic animals is unknown. 
Furthermore, there is probably sufficient variation in 
resilience between individual domestic animals and 
between species that minor differences in pathogenicity 
of strains in domestic animals in different regions may 
not be apparent clinically.  Such seems to be the case in 
Mindanao where the isolate, which was significantly 
less pathogenic in mice than the other isolates from 
Mindanao, was taken from a buffalo with surra that was 
not noticeably clinically different from the other cases 
from which T. evansi isolates were taken. 
On the other hand, the lower pathogenicity in mice 
of the East Javanese isolate as compared to all isolates 
from Mindanao paralleled the pathogenicity of surra in 
domestic animals in Indonesia and Mindanao. Thus, the 
extent to which measurable variations in pathogenicity 
of different isolates of T. evansi in mice reflect a 
biologically significant difference in domestic animals 
is still unresolved.  Results from this study implied that 
a two-fold difference in pathogenicity in mice may 
indicate a similar trend in domestic animals.  However, 
the measurement of minor pathogenicity variation, 
which is common in mice due to their uniform 
susceptibility, may result in greater variability between 
individual domestic animals due to their resilience to T. 
evansi infection. 
Drug efficacy 
No trypanosomes was found in the blood of mice 
infected with any of the T. evansi isolates of Mindanao 
during the 35-day observation period and treated with 
quinapyramine sulphate/chloride, melarsomine 
dihydrochloride or suramin (Table 2). In contrast, two 
of 10 mice infected with either C4 or A9 isolates (5 
mice each) and treated with diminazene aceturate 
(Berenil
®
) had detectable parasitemia (relapsed 
infection) on days 29 and 31, respectively. Both mice 
died 5 days after parasites were detected in their blood. 
On the other hand, parasites were not detected in mice 
infected with the East Javanese isolate and treated with 
any of the drugs. All infected, untreated mice developed 
infection and died subsequently.  Trypanosoma evansi 
infection usually results to 20–100% fatality in mice 
(Perrone et al. 2018).   
Gillingwater et al. (2009) stated that a dosage of 1 
mg kg
-1
 bw of quinapyramine administered for 4 
consecutive days was able to cure all mice infected with 
T. evansi of Chinese origin. Another study reported that 
50% of mice infected with T. evansi from the same 
origin were cured after treatment with quinapyramine at 
a dose rate of 5 mg kg
-1
 bw (Zhou et al. 2004). 
However, Macaraeg et al. (2013) revealed that T. evansi 
isolates from the Philippines were more susceptible to 
more than 3–10 mg kg
-1
 bw of quinapyramine.  In 
addition, the authors suggested that T. evansi isolates 
from Luzon island required a higher dose to cure the 
infection (10 mg kg
-1
 bw) compared to T. evansi from 
Visayas and Mindanao islands (3 - <10 mg kg
-1
 bw). 
Accordingly, the dosage of quinapyramine used in the 
present study was slightly higher than that of the 
previous study (5 mg kg
-1
 bw) following the dose 
regimen recommended by the manufacturer. The fact 
that all infected mice were cured in this study indicated 
that the drug is effective for surra. 
Melarsomine dihydrochloride, as shown in the 
present study, is effective against the 10 Philippine and 
Indonesian T. evansi isolates. This drug is not used in 
the Philippines and Indonesia for surra thus explains the 
sensitivity of these isolates to the drug (Dobson et al. 
2009; Dewi et al. 2019; Dewi et al. 2020). The drug is 
also effective to treat experimental surra in buffaloes at 
JITV Vol. 26 No. 1 Th. 2021: 22-30 
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Table 2. Efficacy of different trypanocides against infection with 10 Mindanao (Philippines) isolates and one East 
Javanese (Indonesia) isolate of T. evansi in mice 
Code Origin 
























10 mg kg-1 
bw 
C1 Philippines 0 ; - 5 ; - 0 ; 100 0 ; 100 0 ; 100 0 ; 100 
C2 Philippines 0 ; - 5 ; - 0 ; 100 0 ; 100 0 ; 100 0 ; 100 
C3 Philippines 0 ; - 5 ; - 0 ; 100 0 ; 100 0 ; 100 0 ; 100 
C4 Philippines 0 ; - 5 ; - 1 ; 80 ** 0 ; 100 0 ; 100 0 ; 100 
C5 Philippines 0 ; - 5 ; - 0 ; 100 0 ; 100 0 ; 100 0 ; 100 
A8 Philippines 0 ; - 5 ; - 0 ; 100 0 ; 100 0 ; 100 0 ; 100 
A9 Philippines 0 ; - 5 ; - 1 ; 80 *** 0 ; 100 0 ; 100 0 ; 100 
A10 Philippines 0 ; - 5 ; - 0 ; 100 0 ; 100 0 ; 100 0 ; 100 
A11 Philippines 0 ; - 5 ; - 0 ; 100 0 ; 100 0 ; 100 0 ; 100 
A13 Philippines 0 ; - 5 ; - 0 ; 100 0 ; 100 0 ; 100 0 ; 100 
EJ1 Indonesia 0 ; - 5 ; - 0 ; 100 0 ; 100 0 ; 100 0 ; 100 
- not applicable, *The number of mice tested for each drug and for each isolate was five, ** Relapsed infection occurred on day 29, ***Relapsed 
infection occurred on day 31 
0.5 mg kg
-1
 bw in Mindanao, Philippines (Dargantes et 
al. in preparation). However, in Africa where the drug 
is used to treat surra in camels,  melarsomine is no 
longer effective at 0.125 mg kg
-1
 bw dose  (Kabi et al. 
2009). In addition, Hébert et al. (2018) reported that 
melarsomine is unable to kill T. equiperdum in the 
central nervous system of infected horses and therefore 
discourages the use of this drug to treat animals 
suffering from a nervous type of dourine and perhaps of 
surra. 
All infected mice treated with suramin in the present 
study were cleared of the parasite. Comparable results 
were reported by Al-Mohammed (2008) and concluded 
that a dosage of 10 mg kg
-1
 bw of suramin is effective 
against T. evansi isolates in Saudi Arabia. In addition to 
being effective in clearing parasitemia in mice, the drug 
also did not have any detectable toxic effects. The 
present study also supports the findings of Gillingwater 
et al. (2007) that suramin is effective against several 
stocks of T. evansi from Brazil, Columbia, Kazakhstan, 
Philippines, Indonesia, Kenya, China and Vietnam. 
Nevertheless, the drug is no longer available in the 
market (Desquesnes et al. 2013). 
Relapse of parasitemia in mice (C4 on days 29 and 
A9 on days 31) treated with diminazene aceturate at a 
dose of 7 mg kg
-1
, indicates that this drug is no longer 
effective in treating the infection with some of the T. 
evansi isolates in Mindanao. This is in line with the 
result of a previous study with Ethiopian T. evansi type 
A and type B treated with diminazene aceturate + 
antypirine (DIM)  and diminazene aceturate + 
phenazone granules (DIM-SEQ) wherein more than 
half of the T. evansi-infected mice relapsed on the 4
th
-
week post-treatment (Mekonnen et al. 2018). 
Interestingly, water buffaloes experimentally infected 
with T. evansi in Mindanao were not also cured by 
diminazene (Dargantes et al. in preparation). Kabi et al. 
(2009) also reported that diminazene aceturate is no 
longer suitable for the treatment of surra amongst 
camels in Uganda. 
The most likely explanation of this result in the 
present study is that the two relapsing isolates had a 
degree of resistance to diminazene aceturate whereas 
the other isolates tested are susceptible. Nevertheless, it 
cannot be deduced as to what extent resistance is likely 
to be demonstrated in domestic animals, causing 
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treatment to be ineffective. This is because the isolates 
of T. evansi screened in the present study were not 
random selection of T. evansi strains in Mindanao and 
the comparative plasma levels and pharmacokinetics of 
diminazene aceturate in mice dosed at 7 mg kg
-1
 with 
those achieved in domestic animals dosed at 3.5 mg kg
-1
 
are unknown. However, the use of diminazene aceturate 
for treatment of surra among animals in Mindanao 
should be discontinued to prevent further development 
of resistance among T. evansi isolates on the island. 
Another possible explanation for the relapsing T. 
evansi infection in mice as observed in this study was 
the failure of diminazene to reach trypanosomes 
invading reserved tissues particularly the brain (Al-
Mohammed 2008; Jatau et al. 2010). Relapsing 
parasitemia was also observed in mice infected with 
tissue-invading T. brucei and T. vivax and treated with 
diminazene aceturate (Qadeer et al. 2013).  
Diminazene has been widely used in Mindanao for 
more than two decades at the recommended dose rate of 
3.5 mg kg
-1 
bodyweight.  It is widely accepted that 
prolonged usage of the same drug, especially at sub-
therapeutic doses, leads to drug resistance which may 
also be aggravated by immunosuppression. Animals 
may be underdosed in the field where bodyweights are 
often estimated roughly, with the consequence that the 
computed dose is usually below the recommended 
therapeutic dose. Immunosuppression may be induced 
by heavy parasite burden, stressful conditions or 
trypanosomiasis (Yayeh et al. 2018). Drug resistance of 
trypanosomes to diminazene aceturate is common in 
African and Asian countries. Evidence of resistance 
was also provided in in vitro and in vivo trials with 
isolates collected from China, Ethiopia and the 
Philippines (Zhou et al. 2004; Nuryady et al. 2019). 
CONCLUSION 
It is concluded that the T. evansi isolates from 
Mindanao, Philippines, tested in this study, are more 
pathogenic than the isolate from East Java, Indonesia, 
with minimal pathogenic heterogeneity among the 
Philippine T. evansi isolates. Quinapyramine 
sulphate/chloride, melarsomine dihydrochloride and 
suramin are effective against the T. evansi isolates 
tested while the use of diminazene against surra in 
Mindanao should be re-evaluated. This information is 
valuable in the enhancement of the control strategy 
against surra in the Philippines and Indonesia.  
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